These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32041819)

  • 1. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis.
    Mirian C; Duun-Henriksen AK; Juratli T; Sahm F; Spiegl-Kreinecker S; Peyre M; Biczok A; Tonn JC; Goutagny S; Bertero L; Maier AD; Møller Pedersen M; Law I; Broholm H; Cahill DP; Brastianos P; Poulsgaard L; Fugleholm K; Ziebell M; Munch T; Mathiesen T
    J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):378-387. PubMed ID: 32041819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutations in primary and secondary WHO grade III meningioma.
    Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
    Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
    Lu VM; Goyal A; Lee A; Jentoft M; Quinones-Hinojosa A; Chaichana KL
    J Neurooncol; 2019 Mar; 142(1):1-10. PubMed ID: 30506498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma.
    Mirian C; Grell K; Juratli TA; Sahm F; Spiegl-Kreinecker S; Peyre M; Biczok A; Tonn JC; Goutagny S; Bertero L; Maier AD; Jensen LR; Schackert G; Broholm H; Scheie D; Cahill DP; Brastianos PK; Skjøth-Rasmussen J; Fugleholm K; Ziebell M; Munch TN; Kristensen BW; Mathiesen T
    Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12773. PubMed ID: 34799864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
    Spiegl-Kreinecker S; Lötsch D; Neumayer K; Kastler L; Gojo J; Pirker C; Pichler J; Weis S; Kumar R; Webersinke G; Gruber A; Berger W
    Neuro Oncol; 2018 Nov; 20(12):1584-1593. PubMed ID: 30010853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT Promoter Mutations and Risk of Recurrence in Meningioma.
    Sahm F; Schrimpf D; Olar A; Koelsche C; Reuss D; Bissel J; Kratz A; Capper D; Schefzyk S; Hielscher T; Wang Q; Sulman EP; Adeberg S; Koch A; Okuducu AF; Brehmer S; Schittenhelm J; Becker A; Brokinkel B; Schmidt M; Ull T; Gousias K; Kessler AF; Lamszus K; Debus J; Mawrin C; Kim YJ; Simon M; Ketter R; Paulus W; Aldape KD; Herold-Mende C; von Deimling A
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26668184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
    Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional fractal dimension and lacunarity features may noninvasively predict TERT promoter mutation status in grade 2 meningiomas.
    Won SY; Lee JH; Lee N; Park YW; Ahn SS; Kim J; Chang JH; Kim SH; Lee SK
    PLoS One; 2022; 17(10):e0276342. PubMed ID: 36264940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and diffusion parameters may noninvasively predict TERT promoter mutation status in grade II meningiomas.
    Shin I; Park YW; Ahn SS; Kang SG; Chang JH; Kim SH; Lee SK
    J Neuroradiol; 2022 Jan; 49(1):59-65. PubMed ID: 33716047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
    Goutagny S; Nault JC; Mallet M; Henin D; Rossi JZ; Kalamarides M
    Brain Pathol; 2014 Mar; 24(2):184-9. PubMed ID: 24261697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
    Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
    Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
    Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U
    Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
    Stögbauer L; Stummer W; Senner V; Brokinkel B
    Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral heterogeneity and
    Juratli TA; Thiede C; Koerner MVA; Tummala SS; Daubner D; Shankar GM; Williams EA; Martinez-Lage M; Soucek S; Robel K; Penson T; Krause M; Appold S; Meinhardt M; Pinzer T; Miller JJ; Krex D; Ely HA; Silverman IM; Christiansen J; Schackert G; Wakimoto H; Kirsch M; Brastianos PK; Cahill DP
    Oncotarget; 2017 Dec; 8(65):109228-109237. PubMed ID: 29312603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.
    Fürtjes G; Köchling M; Peetz-Dienhart S; Wagner A; Heß K; Hasselblatt M; Senner V; Stummer W; Paulus W; Brokinkel B
    J Neurooncol; 2016 Oct; 130(1):79-87. PubMed ID: 27465278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
    Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
    J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.
    Juratli TA; McCabe D; Nayyar N; Williams EA; Silverman IM; Tummala SS; Fink AL; Baig A; Martinez-Lage M; Selig MK; Bihun IV; Shankar GM; Penson T; Lastrapes M; Daubner D; Meinhardt M; Hennig S; Kaplan AB; Fujio S; Kuter BM; Bertalan MS; Miller JJ; Batten JM; Ely HA; Christiansen J; Baretton GB; Stemmer-Rachamimov AO; Santagata S; Rivera MN; Barker FG; Schackert G; Wakimoto H; Iafrate AJ; Carter SL; Cahill DP; Brastianos PK
    Acta Neuropathol; 2018 Nov; 136(5):779-792. PubMed ID: 30123936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARID1A and TERT promoter mutations in dedifferentiated meningioma.
    Abedalthagafi MS; Bi WL; Merrill PH; Gibson WJ; Rose MF; Du Z; Francis JM; Du R; Dunn IF; Ligon AH; Beroukhim R; Santagata S
    Cancer Genet; 2015 Jun; 208(6):345-50. PubMed ID: 25963524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.